Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 15% following the announcement of a licensing agreement with Sihuan Pharmaceutical for the new indication of VV116, aimed at treating RSV and HMPV infections in Greater China [1] Group 1: Company Developments - Wangshan Wangshui has entered into a licensing agreement with Sihuan Pharmaceutical, granting exclusive rights for the use of dextromethorphan hydrobromide in treating RSV and HMPV infections in Greater China [1] - The collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116 [1] Group 2: Product Pipeline - As of October 21, 2025, Wangshan Wangshui has established a diversified pipeline of 9 innovative products, with 2 in the commercialization stage, 4 in clinical stages, and 3 in preclinical stages [1] - The company also has a generic drug segment, with 3 products either commercialized or nearing commercialization [1] - The two core products of Wangshan Wangshui are LV232 and TPN171 [1]
港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议